Sorafenib for Residue Disease After Resection With Curative Intent
Status:
Completed
Trial end date:
2017-09-08
Target enrollment:
Participant gender:
Summary
Radical hepatic resection represents one of the treatment options offering a prospect for
cure with 5-year survival rates up to 50%. However, unintentionally, quite a proportion of
these "radical resection" actually turned out to be non-radical in nature. For these patients
who actually received non-radical resection, their by year survival rates were much lower
than those who received radical hepatectomy. In this prospective, non-interventional,
multi-center study, we are planning to observe the patient characteristics of Hepatocellular
carcinoma (HCC) patients who have residual disease after resection with curative intent, as
well as treatment pattern, safety and effectiveness of sorafenib for these patients.